



ESPERMOGRAMA NO CONSULTÓRIO GINECOLÓGICO

Edson Borges Jr.

**Fertility Medical Group
FERTGROUP
Instituto Sapientiae**

Declaração

**Sem conflito de interesse para divulgar
relacionado ao assunto desta palestra**

**Resolução do Conselho Federal de Medicina
nº 1.595/2.000**

Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021




Figure 1: TFR, globally and by GBD super-region, 1950–2100

The dashed horizontal line indicates replacement TFR (2.1), and the dashed vertical line indicates the year 2022 (the first forecast year). GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. TFR=total fertility rate.




Figure 2 World map containing percentages of infertility cases per region that are due to male factor. This figure demonstrates rates of infertility cases in each region studied (North America, Latin America, Africa, Europe, Central/Eastern Europe, Middle East, Asia, and Oceania) due to male factor involvement.

Physiol Rev 96: 55–97, 2016

Published November 18, 2015; doi:10.1152/physrev.00017.2015

MALE REPRODUCTIVE DISORDERS AND FERTILITY TRENDS: INFLUENCES OF ENVIRONMENT AND GENETIC SUSCEPTIBILITY

**Niels E. Skakkebaek, Ewa Rajpert-De Meyts, Germaine M. Buck Louis, Jorma Toppari,
Anna-Maria Andersson, Michael L. Eisenberg, Tina Kold Jensen, Niels Jørgensen,
Shanna H. Swan, Katherine J. Sapra, Søren Ziebe, Lærke Priskorn, and Anders Juul**

Incidência de Criptorquidia




FIGURE 7. Incidence of cryptorchidism at birth on the basis of prospective clinical studies from the 1950s to the 2000s in Denmark, Finland, and United Kingdom. The data points are marked on the year of the publication of the study which represents the preceding incidence rate (3, 47, 61, 184, 377).

Idade da Puberdade




FIGURE 8. Recent changes in male pubertal timing. Testicular volume was >3 ml. [From Mouritsen et al. (293).]

Incidência de Câncer de Testículo




FIGURE 4. Trends in testicular cancer; age-standardized (world) incidence (regional or national), all ages. [Modified from Znaor et al. (481). Courtesy of Dr. Arinana Znaor and statistician Mathieu Laversanne, M.Sc., WHO, International Agency for Research in Cancer (IARC), Lyon, France.]

Decline in sperm count in European men during the past 50 years

P Sengupta^{1,2}, E Borges Jr³, S Dutta⁴ and E Krajewska-Kulak²





Figure 1. Temporal decline in sperm concentration ($\times 10^6/\text{ml}$) from 1965 to 2015, bubble size corresponds to the number of men in the study.


A time dependent decline in sperm concentration was observed from 1965 to 2015 ($r=0.307$, $p=0.02$)
An overall 32.5% decrease in mean sperm concentration

GRAPHICAL ABSTRACT


Sperm count is declining at an accelerated pace **globally**



101 mill/ml
(1973)



49 mill/ml
(2018)



Sperm count is declining at an accelerated pace globally.

Human Reproduction Update, Vol.29, No.2, pp. 157–176, 2023

Advance Access Publication on November 15, 2022 <https://doi.org/10.1093/humupd/dmac035>

QUANDO INICIAR A AVALIAÇÃO ?

- ➔ Para mulheres < 35 anos: casais com vida sexual normal, após 1 ano de tentativas, sem anticoncepção e sem gestação
- ➔ Para mulheres \geq 35 anos: casais com vida sexual normal, após 6 meses de tentativas, sem anticoncepção e sem gestação
- ➔ Iniciar antes:
 - Caso ♂ tenha um fator de risco conhecido para infertilidade (criptorquidia, patologia endócrina, varicocele, etc..)
 - Caso ♀ tenha um fator de risco conhecido para infertilidade (idade > 35 anos, SOP, etc..)
 - Caso ♂/ ♀ questionem seu potencial fértil

ETIOLOGIA DA INFERTILIDADE MASCULINA

- ***fator masculino: 30% - 40%***
- Infertilidade idiopática: 25-30% dos homens
- Doença multifatorial com fenótipo heterogêneo

***Envolver o marido na
investigação e tratamento!!***

Propedêutica em infertilidade

- fator masculino: 30-40%
- fator ovulatório: 15%
- fator tubo peritoneal
- fator uterino } 35%
- fator cervical
- fator imunológico } 5%
- ISCA: 10 %
- combinados: 35%
- fator psicossomático ?

Propedêutica em infertilidade

● fator masculino: 30-40%

fator ovulatório: 15%

fator tubo peritoneal

fator uterino

} 35%

fator cervical

fator imunológico

} 5%

ISCA: 10 %

combinados: 35%

fator psicossomático ?

Propedêutica em infertilidade

Propedêutica Básica Homem

- Espermograma com morfologia estrita
- Total Motile Sperm Count (TMSC)
- Processamento seminal Prognóstico
- Cariótipo
- Quando alteração seminal importante (conc < 2,0 milhões/ml): avaliação genética (cariótipo, microdeleção Y)
- Quando agenesia de deferentes: pesquisa de CFTR

**WHO manual for the
standardized investigation
of the infertile male**

PATRICK J. ROWE, FRANK H. COMHAAR,
TIMOTHY B. HARGREAVE,
AHMED M. A. MAHMOUD



WORLD HEALTH ORGANIZATION

**ESHRE
Manual on Best Practice
Laboratory Methods**

Editors: U.Kvist and
M. G. Sills

**WHO laboratory manual for the
examination and processing of
human semen**

Sixth Edition



World Health Organization



human reproduction programme
research for impact

II Consenso Brasileiro

**Infertilidade
Masculina**



SBU
Sociedade Brasileira de Urologia


Manual for the
examination and processing

Análise Seminal

VAN LEEUWENHOEK	1677
SIMS	1866
WEISMAN	1940
AMERICAN FERTILITY ASS	1951
FREUND	1966
ELIASSON	1971
<i>O.M.S.</i>	<i>1980/ 87/ 92/ 99/ 2010/ <u>2021</u></i>

WHO laboratory manual for the
**examination and processing of
human semen**

Sixth Edition



WHO laboratory manual for the
**examination and processing of
human semen**

Sixth Edition


	N	Centiles									
		2.5th	5th	(95% CI)	10th	25th	50th	75th	90th	95th	97.5th
Semen volume (ml)	3586	1.0	1.4	(1.3-1.5)	1.8	2.3	3.0	4.2	5.5	6.2	6.9
Sperm concentration (10 ⁶ per ml)	3587	11	16	(15-18)	22	36	66	110	166	208	254
Total sperm number (10 ⁶ per ejaculate)	3584	29	39	(35-40)	58	108	210	363	561	701	865
Total motility (PR + NP, %)	3488	35	42	(40-43)	47	55	64	73	83	90	92
Progressive motility (PR, %)	3389	24	30	(29-31)	36	45	55	63	71	77	81
Non-progressive motility (NP, %)	3387	1	1	(1-1)	2	4	8	15	26	32	38
Immotile spermatozoa (IM, %)	2800	15	20	(19-20)	23	30	37	45	53	58	65
Vitality (%)	1337	45	54	(50-56)	60	69	78	88	95	97	98
Normal forms (%)	3335	3	4	(3.9-4.0)	5	8	14	23	32	39	45

O.M.S. 1980/87/92/99/2010

Table 1. Cut-off values for semen variables as published in consecutive WHO manuals [6–9] and as proposed in the fifth World Health Organization (WHO) manual [1].

Semen variable	1980	1987	1992	1999	2010 ¹
Volume (mL)	–	≥ 2.0	≥ 2.0	≥ 2.0	1.5
Concentration (10 ⁶ mL ⁻¹)	20–200	≥ 20	≥ 20	≥ 20	15
Total sperm number (10 ⁶ /ejaculate)	–	≥ 40	≥ 40	≥ 40	39
Motility (% motile)	≥ 60	≥ 50 (a + b) ²	≥ 50 (a + b)	≥ 50 (a + b)	40 (a + b + c)
Forward progression (for 1980 only)	≥ 2 ³	≥ 25 (a)	≥ 25 (a)	≥ 25 (a)	32 (a + b)
Morphology (% normal)	80.5 ⁴	≥ 50	≥ 30 ⁵	(14) ⁶	4
Viability/vitality (% live)	–	≥ 50	≥ 75	≥ 75	58
White blood cells (10 ⁶ mL ⁻¹)	< 4.7	< 1.0	< 1.0	< 1.0	< 1.0

Fig. 2.1 Variation in total number of spermatozoa and sperm concentration over a one-and-a-half-year period



Análise Seminal

Análise Macroscópica

cor, viscosidade, pH, volume, liquefação

Análise Microscópica

concentração, motilidade, morfologia



Pelo menos duas amostras!

Análise Seminal

Investigação:

- Análise seminal com morfologia estrita
 - 2 amostras (intervalo de 15 dias) ou no intervalo de abstinência ejaculatória
 - padronização da coleta
 - profissional experiente

★ *Fornece dados sobre espermatogênese e permeabilidade do trato reprodutivo*

★ *Ondas de espermatogênese ocorrendo simultaneamente, num mesmo túbulo seminífero*

Abnormal sperm count and motility on semen analysis are not sufficiently predictive of abnormal Kruger morphology

Fertility and Sterility® Vol. 94, No. 7, December 2010

Sara S. Morelli, M.D.^a
 Aimee Seungdamrong, M.D.^{a,b}
 David H. McCulloh, Ph.D.^{a,b}
 Peter G. McGovern, M.D.^{a,b}

Abnormal morphology by Kruger's strict criteria cannot be predicted reliably by the presence of other abnormal parameters on semen analysis. Assessment of Kruger morphology therefore remains a necessary component of a complete semen analysis in the workup of the infertile couple. (Fertil Steril® 2010;94:2882-4. ©2010 by American Society for Reproductive Medicine.)

TABLE 1

Classification of semen analyses.

Count ($\geq 2 \times 10^7$ /mL)	Motility ($\geq 50\%$)	Kruger morphology ($> 4\%$)	No.	Percentage of total
Low	Low	Low	158	11
Low	Low	Normal	58	4
Low	Normal	Low	48	3
Low	Normal	Normal	41	3
Normal	Low	Low	69	5
Normal	Low	Normal	92	7
Normal	Normal	Low	187	14
Normal	Normal	Normal	731	53
Total			1,384	



TMSC (total motile sperm count)

Número total de espermatozoides móveis

= volume x conc/ml x % A+B / 100%

Total motile sperm count: a better indicator for the severity of male factor infertility than the WHO sperm classification system

J.A.M. Hamilton^{1,*}, M. Cissen¹, M. Brandes³, J.M.J. Smeenk²,
J.P. de Bruin¹, J.A.M. Kremer³, W.L.D.M. Nelen³,
and C.J.C.M. Hamilton¹

¹Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands ²St. Elisabeth Hospital, Tilburg, The Netherlands
³Radboud University Medical Center, Nijmegen, The Netherlands

Total Motile Sperm Count: 3 grupos com prognósticos diferentes:

- TMSC < 5 milhões de espermatozóides
- TMSC 5 - 20 milhões de espermatozóides
- TMSC > 20 milhões de espermatozóides




Figure 4 Results showing where the TMSC and WHO classification systems overlap or disagree. The bars on the right and left show the outcome if the two systems are in agreement. The middle bars show the outcome if both systems give contradictory results. TMSC normal – WHO normal = 'real unexplained' infertility.




Figure 4 Results showing where the TMSC and WHO classification systems overlap or disagree. The bars on the right and left show the outcome if the two systems are in agreement. The middle bars show the outcome if both systems give contradictory results. TMSC normal – WHO normal = 'real unexplained' infertility.




Figure 4 Results showing where the TMSC and WHO classification systems overlap or disagree. The bars on the right and left show the outcome if the two systems are in agreement. The middle bars show the outcome if both systems give contradictory results. TMSC normal – WHO normal = 'real unexplained' infertility.

ORIGINAL ARTICLE

Correspondence:

Edson Borges Jr., MD, PhD, Av. Brigadeiro Luis Antonio, 4545, Sao Paulo 01401-002, SP, Brazil.
E-mail: edson@fertility.com.br

*These authors contributed equally to this manuscript.

Keywords:

intracytoplasmic sperm injection, infertility, sperm count, sperm motility, spermatozoa

Received: 18-Dec-2015

Revised: 8-Mar-2016

Accepted: 21-Mar-2016

doi: 10.1111/andr.12199

Total motile sperm count has a superior predictive value over the WHO 2010 cut-off values for the outcomes of intracytoplasmic sperm injection cycles

^{1,2}*E. Borges Jr, ^{1,2}*A. S. Setti, ^{1,2}D. P. A. F. Braga, ¹R. C. S. Figueira and ^{1,2}A. Iaconelli Jr

- ➔ **Definição: $TMSC = volume \times conc/ml \times \% A+B / 100\%$**
- ➔ **518 ciclos de ICSI**
- ➔ **TMSC normal: > 20 milhões**

Table 4 Comparison of ICSI outcomes between normal and abnormal TMSC groups

Variables	Normal TMSC group (<i>n</i> = 328)	Abnormal TMSC group (<i>n</i> = 190)	<i>p</i> -value
Paternal age (year-old)	37.4 ± 4.8	38.1 ± 6.1	0.187
Maternal age (year-old)	35.4 ± 3.9	33.5 ± 4.0	<0.001
Number of aspirated follicles	17.8 ± 9.7	20.8 ± 11.2	0.002
Number of obtained oocytes	12.7 ± 7.2	15.1 ± 8.1	0.001
Number of mature oocytes	9.7 ± 5.5	11.2 ± 6.2	0.003
Number of injected oocytes	9.4 ± 4.3	10.2 ± 4.9	0.067
Fertilization rate (%)	84.9 ± 14.4	81.1 ± 15.8	0.016
Number of obtained embryos	8.2 ± 3.8	8.7 ± 4.4	0.204
Number of transferred embryos	2.2 ± 0.6	2.2 ± 0.5	0.469
Implantation rate (%)	25.1 ± 36.0	25.8 ± 35.2	0.832
Pregnancy rate (%)	134/328 (40.9)	94/190 (49.5)	0.060
Miscarriage rate (%)	29/162 (17.9)	23/78 (29.5)	0.041

SD, standard deviation; TMSC: total motile sperm count.

Table 5 Linear and binary regression analysis results for the influences of TMSC and WHO cut-off values on ICSI outcome

Variables	Method	OR or RC	CI or R^2	p -value
Fertilization rate	Concentration	3.994	1.4%	0.015
	Motility	0.097	0.0%	0.957
	Progressive motility	2.299	0.5%	0.163
	Morphology	8.735	0.9%	0.047
	TMSC	3.784	1.5%	0.013
	Normal TMSC	-0.253	0.1%	0.592
Formation of high-quality zygotes on D1	Concentration	1.64	1.09–2.46	0.018
	Motility	1.34	0.85–2.12	0.208
	Progressive motility	1.22	0.80–1.85	0.355
	Morphology	0.89	0.65–1.22	0.461
	TMSC	1.13	1.01–1.28	0.049
	Normal TMSC	0.99	0.97–1.02	0.629
Formation of high-quality embryos on D2	Concentration	0.93	0.76–1.09	0.101
	Motility	0.91	0.79–1.06	0.222
	Progressive motility	1.06	0.92–1.22	0.420
	Morphology	0.84	0.60–1.18	0.314
	TMSC	1.18	1.03–1.35	0.013
	Normal TMSC	0.97	0.94–1.01	0.098
Formation of high-quality embryos on D3	Concentration	0.91	0.79–1.06	0.229
	Motility	0.93	0.79–1.09	0.379
	Progressive motility	1.00	0.85–1.17	0.969
	Morphology	1.18	0.83–1.67	0.354
	TMSC	1.12	1.07–1.29	0.037
	Normal TMSC	0.98	0.95–1.02	0.319
Formation of blastocyst on D5	Concentration	1.11	0.97–1.27	0.116
	Motility	1.03	0.90–1.19	0.660
	Progressive motility	0.91	0.70–1.23	0.303
	Morphology	1.13	0.83–1.55	0.427
	TMSC	1.16	1.04–1.26	0.011
	Normal TMSC	1.00	0.97–1.04	0.802

Blastocyst expansion grade on D5	Concentration	0.83	0.66–1.05	0.120
	Motility	1.01	0.79–1.29	0.948
	Progressive motility	1.08	0.85–1.38	0.533
	Morphology	0.99	0.57–1.71	0.962
	TMSC	1.27	1.01–1.60	0.042
	Normal TMSC	1.03	0.98–1.07	0.287
Implantation rate	Concentration	2.387	0.1%	0.492
	Motility	–2.916	0.1%	0.453
	Progressive motility	–1.754	0.0%	0.616
	Morphology	6.084	0.0%	0.502
	TMSC	–0.688	0.0%	0.833
	Normal TMSC	1.705	1.0%	0.222
Pregnancy	Concentration	0.71	0.49–1.05	0.083
	Motility	0.77	0.50–1.19	0.242
	Progressive motility	0.72	0.49–1.05	0.089
	Morphology	2.17	0.78–6.07	0.132
	TMSC	1.40	0.98–2.01	0.066
	Normal TMSC	0.94	0.86–1.03	0.200
Miscarriage	Concentration	0.57	0.30–1.08	0.089
	Motility	1.32	0.61–2.85	0.478
	Progressive motility	1.05	0.54–2.05	0.886
	Morphology	0.84	0.17–4.08	0.826
	TMSC	0.52	0.28–0.90	0.045
	Normal TMSC	1.12	0.91–1.26	0.084




Figure 1 Cost per live birth. IUI = intrauterine insemination; ICSI = intracytoplasmic sperm injection; TMC = total motile count.

TMSC (x10 ⁶)	IUI	FIV/ICSI
0,1	0%	21,8%
10,0	10,2%	27,7%

Intrauterine insemination

The ESHRE Capri Workshop Group¹

Although widely utilized, there is little evidence of the effectiveness in male infertility (Bensdorp *et al.*, 2007), and one large trial found that stimulated IUI was not effective in the treatment of unexplained infertility (Steures *et al.*, 2006).

Approaches to improve the diagnosis and management of infertility

human
reproduction
update

P. Devroey^{1,4}, B.C.J.M. Fauser² and K. Diedrich³ on behalf of the
Evian Annual Reproduction (EVAR) Workshop Group 2008[†]

Human Reproduction Update, Vol.15, No.4 pp. 391–408, 2009

*AS adequada para alterações seminais graves;
para alterações moderadas/leves: inadequada*

Approaches to improve the diagnosis and management of infertility

human
reproduction
update

P. Devroey^{1,4}, B.C.J.M. Fauser² and K. Diedrich³ on behalf of the
Evian Annual Reproduction (EVAR) Workshop Group 2008[†]

Human Reproduction Update, Vol.15, No.4 pp. 391–408, 2009

- *Fator masculino leve/moderado:
FIV / ICSI = 6 ciclos IIU*
- *ESCA e IIU: eficiência ??*
- *Quando indicada TRA: FIV / ICSI em
todos casos de fator masculino*
- *ICSI leva < falha fertilização*

REPRODUÇÃO ASSISTIDA

“QUANDO INDICAR”

➔ COITO PROGRAMADO:

. TMSC > 20 milhões, morfologia estrita > 4 %

➔ INSEMINAÇÃO ARTIFICIAL (IIU):


. TMSC > 5 milhões, morfologia estrita > 4%

➔ FERTILIZAÇÃO “IN VITRO” (FIV):

. TMSC 1 - 5 milhões, morfologia estrita > 4%, falha em 3 IIU

INJEÇÃO INTRA-CITOPLASMÁTICA (ICSI):

- ➔ . TMSC < 1 milhão, morfologia estrita < 4%,
- . falha de fertilização FIV,
- . ESCA



*Qualidade do Espermatozoide
X
Chances de Sucesso*

Qualidade seminal e resultados de T.R.A.



ANDROLOGIA 30, 5

The outcome of intracytoplasmic sperm injection

R. Mercan, S. E. Lan

The Howard and Georgan
Virginia Medical School, No

Andrology: The results of the first three basic sperm parameters

Z.P. Nagy, J. Liu, H. Joris, G. Verheyen

Human Reproduction, Volume 10, Issue 1, February 1995

<https://doi.org/10.1093/oxfordjour>



Ragaa T. M. ...
Mohamed A. Abou...
Gamal I. Serour, M.D.*§

The Egyptian IVF-ET Center, Cairo Univers...

Journal Article

... is not related to any of the

ACCEPTED: SEPTEMBER 16, 1997

Lowering intracytoplasmic sperm injection semen quality

and S. Oehninger

etrics and Gynecology Eastern

J.*
izi, M.D.*‡


har University, Cairo, Egypt

Consequências da Alteração Espermática

- ➔ menores taxas de fertilização
- ➔ desenvolvimento embrionário inadequado
- ➔ maiores taxas de aborto
- ➔ piores condições perinatais
- ➔ maior incidência de doenças epigenéticas
- ➔ maiores taxas de malformações...

Slama et al, 2005, Nybo Anderson et al, 2004, Bille et al, 2005, Nieschlag et al, 2004, Tesarik et al, 2006, Wyrobek et al, 2006, Borini et al, 2007. Middelburg et al, 2008 ...

FERTILITY MEDICAL GROUP 2005 - 2023



Influência da qualidade do espermatozoide ejaculado nos resultados de ICSI – JBRA, 5: 22-26, 2001

Borges Jr. E., et al

	< 1 x 10⁶/ml motilidade <10%	sem fator masculino	P
Ciclos / pacientes	105 / 82	184 / 141	
Fertilização Normal (2PN)	628 (36,0%)	1256 (67,8%)	0,014
Oócitos não-fertilizados	942 (54,1%)*	362 (19,6%)	0,025
Bons embriões	44,5%	87,1%	0,029
Gestação / ciclo	31,4%	29,9%	0,216
Gestação/ paciente	40,8%	38,9%	0,067
Abortamento	43,5% (10/33)	25,4 % (14/55)	0,012

* Idade materna ≤ 35 anos e Número de ovócitos recuperados ≥ 4

Use of suboptimal sperm increases the risk of aneuploidy of the sex chromosomes in preimplantation blastocyst embryos

Alison Coates, B.Sc.,^{a,b} John S. Hesla, M.D.,^a Amanda Hurliman, M.D.,^a Breanne Coate, B.S.,^a Elizabeth Holmes, M.S.,^a Rebecca Matthews, Ph.D.,^a Emily L. Mounts, M.S.,^a Kara J. Turner, Ph.D.,^b Alan R. Thornhill, Ph.D.,^{b,c} and Darren K. Griffin, D.Sc.^b

- ➔ A infertilidade masculina grave está associada a *um aumento significativo na ocorrência de anormalidades dos cromossomos sexuais em blastocistos*, em comparação com embriões derivados de amostras de sêmen normais.
- ➔ As *taxas de aneuploidia* em embriões derivados de sêmens com *parâmetros normais* não foram significativamente diferentes se *ICSI ou inseminação padrão* foi usada para obter a fertilização.

Effect of the male factor on the clinical outcome of intracytoplasmic sperm injection combined with preimplantation aneuploidy testing: observational longitudinal cohort study of 1,219 consecutive cycles

Rossella Mazzilli, M.D.,^{a,b} Danilo Cimadomo, M.Sc.,^{b,c} Alberto Vaiarelli, M.D.,^{b,d} Antonjo Capalbo, Ph.D.,^{b,e} Lisa Dovere, Ph.D.,^b Erminia Alviggi, M.Sc.,^f Ludovica Dusi, Ph.D.,^g Carlo Foresta, M.D.,^h Francesco Lombardo, M.D.,ⁱ Andrea Lenzi, M.D.,ⁱ Herman Tournaye, M.D.,^j Carlo Alviggi, M.D.,^k Laura Rienzi, M.Sc.,^{b,f,g} and Filippo Maria Ubaldi, M.D.^{b,f,g}

VOL. 108 NO. 6 / DECEMBER 2017

➔ O fator masculino grave prejudica a competência embrionária precoce em termos de *taxa de fertilização e potencial de desenvolvimento*.



Male factor infertility impacts the rate of mosaic blastocysts in cycles of preimplantation genetic testing for aneuploidy

Nicoletta Tarozzi¹ · Marco Nadalini¹ · Cristina Lagalla¹ · Giovanni Coticchio¹  · Carlotta Zacà¹ · Andrea Borini¹

- ➔ Taxa significativamente *maior taxa de blastocistos em mosaico* foi observada no *grupo MF (3,6% vs. 0,5%, respectivamente; P = 0,03)*.
- ➔ Taxa significativamente *maior de blastocistos em mosaico* foi observada no *grupo SMF (7,7% e 1,8%, respectivamente; P = 0,008)*.

Table 1. Comparison of cycle characteristics and clinical outcomes between ICSI cycles with Normal Sperm Parameters, Male Factor Infertility (< 20M sptz /mL), and Severe Male Factor Infertility (< 1M sptz /mL) .

Variable	Normal sperm parameters	Male factor infertility	Severe male factor infertility	p
Cycles n=3678	2583	795	300	
Female age (years)	33.1 ± 3.8	33.3 ± 2.4	33.8 ± 2.8	0.451
Male age (years)	37.545 ± 0.5	37.870 ± 0.4	37.490 ± 0.2	0.478
Retrieved oocytes (n)	11.2 ± 1.2	17.4 ± 1.0	17.8 ± 4.6	0.384
Fertilization (%)	89.5 ± 8.4	89.8 ± 2.3	88.9 ± 2.8	0.475
High quality embryos rate (%)	31.8 ± 1.0 ^a	27.1 ± 2.4 ^b	24.9 ± 3.0 ^c	<0.001
Blastocyst formation (%)	43.3 ± 4.4	44.3 ± 4.4	38.5 ± 3.8	0.263
Implantation rate	40.4 ± 0.8 ^a	33.6 ± 0.5 ^b	28.5 ± 1.0 ^c	< 0.001
Pregnancy Rate	47.0 ± 5.8 ^a	44.0 ± 2.5 ^{a,b}	35.0 ± 7.3 ^b	0.045
Miscarriage Rate	8.4 ± 6.8 ^a	10.3 ± 5.7	12.4 ± 8.4	0.351

Note: Values are means ± standard errors. a#b#c



Table 2. Incidence of euploidy among ICSI cycles with Normal Sperm Parameters, Male Factor Infertility (< 20M sptz /mL), and Severe Male Factor Infertility (< 1M sptz /mL) .

Variable	Normal sperm parameters	Male factor infertility	Severe male factor infertility	p
Cycles n=813	540	198	75	
Biopsied Embryos	1,140	270	120	
Euploidy rate	71.0 ± 17.1 ^a	50.2 ± 35.4 ^{a,b}	44.0 ± 6.4 ^b	0.035

Considerações



- ➔ Diminuição da fertilidade masculina, mais acentuada nas últimas duas décadas;
- ➔ Análise seminal deve ser realizada segundo as normas da OMS 2021;
- ➔ IIU ineficiente para o fator masculino, principalmente para os casos de grande alteração seminal;
- ➔ TMSC mais preciso que a AS tanto para a concepção natural quanto para as TRA;
- ➔ Quanto maior a alteração seminal, menor a eficiência do espermatozoide nas TRA.



Direção

Assumpto Iaconelli Jr.
Edson Borges Jr.



Pesquisa e Educação

Instituto Sapientiae

Amanda Setti
Christina Morishima
Daniela Braga
Raphaela Medeiros




Psicologia

Rose M. Melamed




Laboratório de FIV

Beatriz Muller
Livia Silvia Vingris
Lyvia E. Busso
Patrícia Guilherme
Rodrigo Rosa Provenza
Tatiana Nunes de Melo



Corpo Clínico

Carla Iaconelli
Carolina Rossoni
Edward Carrilho
Fernanda Montenegro
Fábio Biaggioni Lopes
Mário Firmino
Mauro Bibancos
Natalia G. Tannous
Natália Martelli



Anestesiologia

Marcelo Torres
e Equipe



Laboratório de Andrologia

Rodrigo Rosa Provenza
Debora Hernandez



Nutrição

Gabriela Halpern



Enfermagem

Alcione Bispo
Gabriela Lima Almeida
Larissa Rodrigues Gonçalves
Letícia Firmino
Maria Regina S. da Silva
Patrícia Castro
Vera Lucia Alves



Suporte

Genilson Souza
Hugo Oliveira dos Reis
Janaína Gomes Pinho da Silva
Jicélia Santos
João Lucas Ramos
Joice Procópio
José Roberto Duarte
Leidivânia Cerqueira Alves
Marcela Rosa Anjos
Sérgio Luis da Silva
Simone de S. Carvalho
Zenilda da Conceição Souza



Administração

Ana Carolina Santos
Josué B. Santos
Katia Rodrigues
Lucácio de S. Anjos
Margaret Meira



Informática

Anderson Veloso
Marcelo Alexandre Baptista



Farmácia

Maria das N. Fernandes



Comunicação e Marketing

Larissa Nishiwaki





Obrigado!

Dr. Edson Borges Jr.
www.fertility.com.br
E-mail: edson@fertility.com.br